Accordingly, we sought to expand on the UNLOAD trial findings by analysis of a prospective registry of UF patients who were stratified by LVEF. We hypothesized that UF could be used in the HFPEF population with outcomes similar to those with HFLEF.
T here are over 1 000 000 hospitalizations for the primary diagnosis of acute decompensated heart failure (ADHF) in the United States, associated with an estimated cost of $29 billion annually. 1, 2 Beyond loop diuretic therapy, proven treatment options are limited, with unsatisfactory results using inotropic support, 3, 4 vasodilation, 5 vasopressin, 6 and endothelin inhibition. 7 A recent addition to the in-hospital treatment algorithm for HF is ultrafiltration (UF), a mechanical method of volume removal with several potential advantages over usual care. Putative benefits of UF include more effective sodium removal 8 and less neurohormonal stimulation. 9 Although conclusive data on the overall benefit and identification of potential subpopulations most likely to benefit from UF remain unclear, there is a suggestion that ADHF with preserved left ventricular ejection fraction (LVEF; heart failure with preserved ejection fraction [HFPEF]) might be effectively managed with UF. Indeed, in the Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure (UNLOAD) trial that showed superior volume and weight reduction with UF compared with usual care, 10 some patients (59 of 200, 30%) had an LVEF >40%. Furthermore, established indication for UF does not distinguish patients based on LVEF. Although the treatment goal of symptom relief through volume removal remains similar to heart failure patients with low LVEF (HFLEF), 11 pathophysiological differences embodied by higher end-systolic and arterial elastances [12] [13] [14] are manifested by a greater drop in blood pressure (BP) with similar changes in central volume. 12 The downstream effects of UF on these pathophysiological differences between HFPEF and HFLEF patients, specifically on renal function, are not well known. Consequently, the need to study acutely decompensated HFPEF patients treated with UF remains valid.
Methods Patients
The database and its design were approved by the Institutional Review Board of The Christ Hospital, Cincinnati, OH. All patients admitted to The Christ Hospital inpatient HF service for ADHF who were treated with UF, regardless of LVEF, were entered into a prospective database. Selection of UF as the primary treatment method was the choice of the involved HF specialist; generally, patients with >10 lbs of estimated volume overload or evidence of inadequate response to intravenous diuretic administration (urine output <125 mL/h) were referred for UF. Otherwise, there was no explicit protocol guidance for patient selection. Patients had to be able to tolerate insertion of a brachial or internal jugular venous line for access, as well as heparin infusion. LVEF was recorded in the database based on the most recent available value before admission; these values are available in the chart as part of the HF core measures set. The time between the last LVEF determination and admission was not recorded in the registry. Nonetheless, the vast majority of these values were obtained from echocardiograms performed in our institution's laboratories (accredited by the Intersocietal Commission for the Accreditation of Echocardiography Laboratories) and read by board-certified cardiologists as part of routine clinical practice. As part of the Intersocietal Commission for the Accreditation of Echocardiography Laboratories certification, routine technologist and physician education and correlations are performed. Only those patients with recorded weights on admission, UF initiation, UF cessation, and discharge were included in the current analysis; patients were divided into those with HFLEF (LVEF ≤40%) and HFPEF (LVEF >40%).
Protocol
Ultrafiltration was performed for each patient using the Aquadex 100 system (CHF Solutions, Inc, now Gambro) on a telemetry unit, specially dedicated to heart failure treatment, with a patient to nurse ratio of no more than 2:1. Sixty-nine percent of patients in HFLEF and 57% in HFPEF were treated via brachial vein extended length catheter and the rest via internal jugular access. The extended length catheter is a 6F, 15-cm, dual lumen catheter provided by the makers of the Aquadex system, inserted by the peripherally inserted central catheter team. All UF patients received intravenous heparin to maintain activated partial thromboplastin time between 70 and 90 seconds (after July 2009, antifactor X levels between 0.3 and 0.7 IU/mL). Although loop and thiazide diuretics were discontinued, spironolactone was continued. None of the patients received concurrent intravenous vasodilator or inotropic therapies. The in-line hematocrit sensor was not used routinely and did not figure into clinical decisions. Discontinuation of treatment and fitness for discharge were made by the treating heart failure physician based on clinically assessed volume status, symptoms, and objective data, such as laboratory values. Death rates at 90 days postdischarge were obtained through examination of the social security database.
Statistical Analysis
The χ 2 test was used to test categorical variables, whereas continuous variables with a normal distribution were tested with the Student t test. The paired t test was used to compare values before and after UF. Non-normally distributed variables were analyzed with Wilcoxon rank-sum test and presented as the median with interquartile range. P≤0.05 was considered to be significant. All data were analyzed using R 2.15.1 statistical package.
For 90-day survival, we fit the data using a Cox proportional hazards model. Of the covariates in question, a modest correlation was found between total weight loss for admission and the total UF run time, as well as between length of stay and time to UF initiation. It was decided to not include total UF run time and time to UF initiation in the Cox model. The first model considered the effects of covariates that were most likely to influence survival: EF group, age, sex, change in creatinine after UF, length of stay, and total weight loss for admission. Although the full model gave a P value of 0.0076, many of the covariates did not reach significance. Covariates were removed from the model using backward elimination until a final model was obtained with remaining covariates (except for our main effect, EF group) reaching significance level ≤0.05. The final Cox model adjusts for age on EF group and has a P value of 0.0084. EF group was found to have a β coefficient of −0.58, translating to the HFPEF group trending toward a better chance of survival than the HFLEF group (P=0.0885). Age (β coefficient=0.03) had a positive effect on survival in the model (P=0.0167).
Results
We analyzed 87 patients in the HFLEF group and 97 in HFPEF. As shown in Table 1 , the HFPEF patients were more Numbers of patients with available data for median daily furosemide dose were 26 in HFLEF and 57 in HFPEF. Mean±SD, except BNP, median daily furosemide dose, BUN, and creatinine, are presented as the median with 25th and 75th interquartile ranges. BNP indicates brain natriuretic peptide; BUN, blood urea nitrogen; GFR, glomerular filtration rate; Hct, hematocrit; HFLEF, heart failure with low left ventricular ejection fraction; HFPEF, heart failure with preserved ejection fraction; and LVEF, left ventricular ejection fraction.
likely women (52.6% versus 26.4), less likely to have ischemic cause (44.3% versus 65.5%), heavier (259 versus 220.6 lbs), and had higher systolic BP (128.5 versus 112.3 mm Hg) and lower B-type natriuretic peptide levels (347 versus 1125 pg/mL). Based on a limited number of patients for whom data were available, median daily furosemide dose before initiation of UF for HFLEF was 206.5 mg (interquartile range, 10-240 mg; n=26) and for HFPEF, 210 mg (interquartile range, 40-288 mg; n=57).
In terms of the UF protocol, therapy was started at median of 40.6 (21.2-66.6) hours after presentation to the hospital in HFLEF and 30.5 (17.5-77.1) hours in HFPEF. (Table 2 ) Average UF rate was ≈180 mL per hour for both groups. In terms of unintended UF interruptions during the course of therapy for technical reasons, ≈73% of HFLEF patients and 60% of HFPEF experienced ≥1 interruption (P=0.14). In both groups, the vast majority of these interruptions were for clotting of the filter. There were no reported interruptions for symptomatic hypotension, bleeding, or thrombosis.
In both groups, weight loss between admission and initiation of UF was minimal (0.4 lbs in HFLEF and 1.2 lbs in HFPEF; Table 2 ). During UF treatment, weight loss in the 2 groups was similar (16.7 lbs in HFLEF and 14.1 lbs in HFPEF); however, the HFLEF group did not lose further weight in the period between UF cessation and discharge (203.5-203.7 lbs; P=0.72), whereas the HFPEF group lost on average 2.7 lbs more (243.7-241.0 lbs; P=0.07). These changes in weight by stages are represented in Figure 1 .
In totality, the 2 groups responded similarly to UF treatment. Both groups lost significant amount of weight (7.7% of baseline weight in HFLEF and 7.0% in HFPEF; between-group comparison P=0.73; Table 2 ). Systolic BP decreased in both groups by 5 to 6 mm Hg, and both manifested signs of volume contraction, with tendency for higher blood urea nitrogen and creatinine levels at the end of UF treatment (Table 3 ). However, we did observe that creatinine levels were unchanged from UF cessation to discharge in HFLEF ( Mean±SD, except time to UF start and total UF run time, are presented as the median with 25th and 75th interquartile ranges. HFLEF indicates heart failure with low left ventricular ejection fraction; HFPEF, heart failure with preserved ejection fraction; and UF, ultrafiltration. evidence of hemoconcentration in terms of hematocrit elevation, drawn with routine morning laboratories. In both groups, sodium levels were lower at discharge, although, importantly, potassium levels were higher (Table 3) .
Hospital lengths of stay were the same, with 8 days (5-11.5 days) for HFLEF and 8 days (6-13 days) for HFPEF (Table 4 ). In-hospital mortality rates were 3 of 87 (3.4%) in HFLEF and 2 of 97 (3.3%) in HFPEF. Number of deaths at 90 days postdischarge tended to be greater in HFLEF, 21 (24.1%), compared with HFPEF, 15 (15.5%). Cox proportional hazards plot of age-adjusted mortality is shown in Figure 2 .
Discussion
Our findings based on a large cohort of HFPEF patients treated with UF suggest that this population responds similarly to patients with reduced LVEF. Between-group comparisons of changes in weights and other clinical parameters show no significant difference between HFLEF and HFPEF.
The HFPEF patient characteristics of our cohort are consistent with other databases of such patients, [15] [16] [17] with a preponderance of female patients and a greater likelihood of hypertensive, nonischemic cause of heart failure. The findings of this study are reassuring in that UF may be safely applied to the preserved LVEF patients with volume overload, with a reasonable expectation of efficacy similar to the low LVEF population. This is not entirely surprising in that the pathophysiological mechanisms underlying acute decompensation and volume overload are similar in the 2 groups of patients. 11, 15, 18 Whether UF represents a superior method of treatment compared with usual care for these patients in the acute setting remains to be seen.
The recent report of the landmark Cardiorenal Recue Study in Acute Decompensated Heart Failure (CARRESS-HF) study 19 has raised concerns about the safety and use of UF in the management of patients with ADHF with reduced or preserved LV ejection fraction, complicated persistent congestion, and worsening renal function. This direct comparison of 94 patients treated with stepped pharmacological therapy versus 94 patients treated with UF had a bivariate end point of change from baseline in serum creatinine and body weight. There was a similar amount of weight loss seen in both groups. However, preservation of renal function at 96 hours was superior in the stepped pharmacological therapy group. Should the findings of CARRESS-HF affect the interpretation of our study? The answer depends on whether the patients in the 2 studies are comparable. Prestudy furosemide equivalents in CARRESS-HF were 120 mg per day; in our study, furosemide equivalents before starting UF were >210 mg per day. However, as a result of the small number of data available (Table 1) , this comparison is suboptimal. Sixty-day mortality rate in CARRESS-HF was 17% in the UF arm compared with 24% 90-day mortality in the HFLEF arm of our study. These rates seem to be fairly similar. Obviously, as an uncontrolled study, our analysis can only comment on the comparison between HFLEF and HFPEF groups and remain silent on the relative efficacy of UF versus usual care in either group. We do not extrapolate the findings from CARRESS-HF to HFPEF patients, because the interplay between a more predictable rate of volume removal (UF) and the pressure-volume slope is unknown in the clinical setting.
Does the ≈10-day length of stay for both groups suggest these patients may not be comparable with the typical patients seen for ADHF? In the Acute Decompensated Heart Failure National Registry (ADHERE), a large clinical cross section, the average length of stay was 5 days for HFLEF (n=25 865) and 4.9 days for HFPEF patients (n=26 322). 17 However, our patients were those who by virtue of their selection for UF were likely to be sicker, with greater estimated target volume to be removed and evidence of diuretic resistance. Compared with patients in the ADHERE registry, our patients had lower systolic BP (112.3 versus 139 mm Hg in HFLEF, 128.5 versus Length of stay presented as the median with 25th and 75th interquartile ranges. HFLEF indicates heart failure with low left ventricular ejection fraction; and HFPEF, heart failure with preserved ejection fraction. Between-group P values refer to between-group comparisons of changes. Mean±SD, except BUN, creatinine, and BNP, are presented as the median with 25th and 75th interquartile ranges. BNP indicates brain natriuretic peptide; BP, blood pressure; BUN, blood urea nitrogen; Hct, hematocrit; HFLEF, heart failure with low left ventricular ejection fraction; HFPEF, heart failure with preserved ejection fraction; and UF, ultrafiltration. *P<0.05 vs corresponding HFLEF value. †P<0.05 vs before UF.
153 mm Hg in HFPEF), higher blood urea nitrogen (49.3 versus 30 mm Hg in HFLEF, 45.3 versus 29 mg/dL in HFPEF), and creatinine (1.77 versus 1.6 mg/dL in HFLEF, 1.92 versus 1.7 mg/dL in HFPEF). 17 This conclusion is supported by the relatively high 90-day mortality rates of 24.1% and 15.5% in HFLEF and HFPEF groups, respectively. The impact of UF on weight change for the entire hospitalization is similar in HFLEF versus HFPEF, with comparable changes in electrolyte values and renal function. Rises in serum blood urea nitrogen and creatinine levels were seen in both groups; whether these observations represent significant deleterious events or transient markers of decongestion is not clear because of the lack of a diuretic control group or follow-up renal function. However, we did observe that creatinine levels were unchanged from UF cessation to discharge in HFLEF (1.82 [1.3-2.7] to 1.84 [1.3-2.6]; P=0.89) and HFPEF (1.65 [1.2-2.6] to 1.82 [1.2-2.7]; P=0.65); P=0.5 for intergroup difference. This is not surprising in that typically a creatinine rise is used in conjunction with clinical status to signal a reasonable time to stop UF, and stability of renal function is a requisite for discharge. Nonetheless, 90-day death rates do appear to be higher than expected, and it is possible that UF may have had a deleterious medium-term clinical effect that is more pronounced in the HFLEF group.
Changes in weight at various time points are of interest. There is no significant weight loss between admission and UF initiation in these diuretic-resistant patients, despite conventional therapy for over significant number of hours. However, the relative contribution of UF to the overall weight loss is less in HFPEF than in HFLEF. The HFPEF patients continued to lose weight during the period between UF cessation and discharge; 15% of the total weight loss in HFPEF was achieved in the period between UF cessation and discharge. The exact duration of this time period is not clear because in ≈35% of the patients, the UF treatment was not continuous. Nonetheless, it seems that compared with HFLEF patients, HFPEF patients' response to usual care in the period after UF was relatively greater, even if small in magnitude. Mechanisms to explain this observation might include the potential to be more aggressive with diuretic therapy, given the higher BP in the HFPEF group as well as a differential effect of UF-mediated volume removal on cardiorenal physiology and neurohormonal activation between HFLEF and HFPEF.
Despite similar amounts of weight loss, the change in B-type natriuretic peptide is relatively greater in HFPEF. The reasons for this finding are not clear, because clinically both groups appeared improved and ready for discharge. It is possible that similar amounts of volume removed represent a more complete decongestive treatment in the HFPEF, as it is known that through a steeper pressure-volume relationship, patients with HFPEF require smaller volume changes to achieve comparable filling pressure drops and that doses of diuretics required are generally less in HFPEF patients compared with HFLEF patients. 20 There are operational challenges to UF that apply to most patients receiving this treatment, regardless of whether they have decreased or preserved systolic function.
In most patients in the current study, UF was not begun early, particularly as diuretic resistance is the typical indication for UF initiation. However, further delay may be reflective of the associated patient flow limitations that exist in many tertiary care hospitals from point of contact in the emergency department until transfer to an inpatient unit and initiation of more definitive therapy under the heart failure team's guidance. This uncontrolled pretreatment period may have impacted our observations, because HFLEF and HFPEF patients may have been subject to potential disparity in diagnosis and treatment of acute heart failure based on LVEF. However, similar lack of weight loss in the period between presentation and UF initiation minimizes the effect of this potential confounder
Limitations
This study is not a randomized clinical trial, but rather a cohort study. As such, it cannot evaluate the relative effectiveness or safety of UF compared with usual care. The database elements are also limited, without extensive baseline clinical and pharmacological data, urine output, input and output information, and adequate follow-up after discharge. In future study designs, these limitations should be addressed.
Conclusions
In a nonrandomized, prospective observational study comparing ADHF patients stratified by LVEF, we observed in both HFLEF and HFPEF a similar mild drop in BP, rise in blood urea nitrogen and creatinine, as well as a drop in serum sodium and rise in serum potassium. Overall length of stay, weight loss, and in-hospital mortality are similar between HFLEF and HFPEF. Therefore, UF may be a viable treatment option in those ADHF patients with preserved LVEF. Further investigation is required to better define the potential advantages of the more prescribed, accurate, and predictable degree of volume removal with ultrafiltration in this population.
CLINICAL PERSPECTIVE
Volume removal in acute decompensated heart failure (ADHF) patients remains the primary therapeutic objective in the vast majority of hospitalized patients. To that end, ultrafiltration (aquapheresis) has been evaluated in clinical trials and is Food and Drug Administration approved. However, the vast majority of patients studied with ultrafiltration have been those with low left ventricular ejection fraction (LVEF). Nearly half the patients admitted to the hospital for ADHF have an LVEF in the preserved range. In the acute setting, treatment of volume overload in these patients remains similar to those with low LVEF, generally based on loop diuretics. However, there are physiological differences between ADHF patients with preserved and low LVEF, in particular, the relationship between ventricular filling pressure and volume change, which should be considered during decongestion treatment. We compared the clinical course of ADHF patients with preserved LVEF (>40%) with patients with low LVEF (≤40%). In totality, the 2 groups seem to respond similarly. Overall length of stay, weight loss, and in-hospital mortality are similar between heart failure with low left ventricular ejection fraction and heart failure with preserved ejection fraction. Therefore, we conclude that ultrafiltration may be a viable treatment option in those ADHF patients with preserved LVEF, at least to a similar extent as in patients with low LVEF. Further investigation is required to better define the potential advantages of the more prescribed, accurate, and predictable degree of volume removal with ultrafiltration in this population.
